Rentschler Biopharma Takes First Steps in US Expansion Project
Rentshler Biopharma has begun its expansion project in the United States by putting a single-use bioreactor into operation at the Milford facility in Massachusetts.
Rentshler Biopharma, a contract development and manufacturing organization (CDMO) headquartered in Germany, has begun its expansion project in the United States by putting a single-use bioreactor into operation at the Milford facility in Massachusetts.
In a Nov. 6, 2019 press release, the company announced that the XDR-500 bioreactor, which has a working volume of 100–500 L and downstream capabilities of 2–8 g/L, will be part of the good manufacturing practice (GMP) facility suite concept. The company anticipates that the system will be ready for clients by mid-2020, and it is currently being prepared for technology transfer.
Additionally, Rentshler Biopharma revealed some other expansion plans, including another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing and will feature lab capacity for new modalities. Through its client-centric approach, the company aims to facilitate robust and scalable production of complex biomolecules in both Europe and the US.
Source: Rentschler Biopharma
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
